Peter David Suzdak
Director/Board Member at Acidophil LLC
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John McManus | M | 60 | 19 years | |
| Philip Goelet | M | - |
Acidophil LLC
 Acidophil LLC Medical/Nursing ServicesHealth Services Acidophil LLC develops biotechnologies and products in the field of applied genetics and molecular engineering. It uses synthetic biology and/or synthetic chemistry to apply the lessons of evolution to the discovery and development of novel bioactive compounds and related production processes for a variety of market sectors. The company was founded by Sydney Brenner and Philip Goelet and is headquartered in Lutherville, MD. | 18 years |
| Lars Fruergaard Jorgensen | M | 58 | 33 years | |
| Sydney Brenner | M | - |
Acidophil LLC
Acidophil LLC Medical/Nursing ServicesHealth Services Acidophil LLC develops biotechnologies and products in the field of applied genetics and molecular engineering. It uses synthetic biology and/or synthetic chemistry to apply the lessons of evolution to the discovery and development of novel bioactive compounds and related production processes for a variety of market sectors. The company was founded by Sydney Brenner and Philip Goelet and is headquartered in Lutherville, MD. | 18 years |
| Jeffrey Scott | M | 67 | 11 years | |
| John Clerici | M | 54 | 11 years | |
| Amit Kumar | M | 59 | 20 years | |
| Chris Rallis | M | 70 | 20 years | |
| John Farah | M | 72 | 19 years | |
| Mitchell Kaye | M | 56 | 11 years | |
| Martin A. Mullins | M | - |
Acidophil LLC
Acidophil LLC Medical/Nursing ServicesHealth Services Acidophil LLC develops biotechnologies and products in the field of applied genetics and molecular engineering. It uses synthetic biology and/or synthetic chemistry to apply the lessons of evolution to the discovery and development of novel bioactive compounds and related production processes for a variety of market sectors. The company was founded by Sydney Brenner and Philip Goelet and is headquartered in Lutherville, MD. | - |
| Simon Aspland | M | - |
Acidophil LLC
Acidophil LLC Medical/Nursing ServicesHealth Services Acidophil LLC develops biotechnologies and products in the field of applied genetics and molecular engineering. It uses synthetic biology and/or synthetic chemistry to apply the lessons of evolution to the discovery and development of novel bioactive compounds and related production processes for a variety of market sectors. The company was founded by Sydney Brenner and Philip Goelet and is headquartered in Lutherville, MD. | 22 years |
| Kathy Miller | F | - |
Acidophil LLC
Acidophil LLC Medical/Nursing ServicesHealth Services Acidophil LLC develops biotechnologies and products in the field of applied genetics and molecular engineering. It uses synthetic biology and/or synthetic chemistry to apply the lessons of evolution to the discovery and development of novel bioactive compounds and related production processes for a variety of market sectors. The company was founded by Sydney Brenner and Philip Goelet and is headquartered in Lutherville, MD. | - |
| Maziar Mike Doustdar | M | 54 | 32 years | |
| John Halberstadt | M | - |
Acidophil LLC
Acidophil LLC Medical/Nursing ServicesHealth Services Acidophil LLC develops biotechnologies and products in the field of applied genetics and molecular engineering. It uses synthetic biology and/or synthetic chemistry to apply the lessons of evolution to the discovery and development of novel bioactive compounds and related production processes for a variety of market sectors. The company was founded by Sydney Brenner and Philip Goelet and is headquartered in Lutherville, MD. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Douglas Swirsky | M | 54 | 2 years | |
| Russell Skibsted | M | 65 | 3 years | |
| Chang Ho Ahn | M | 72 | 16 years | |
| Michael P. McManus | M | 54 | 5 years | |
| Tae Heum Jeong | M | 53 | 15 years | |
| David H. Bergstrom | M | 70 |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 1 years |
| Kåre Schultz | M | 62 | 26 years | |
| Lise Kingo | F | 62 | 26 years | |
| Mark P. Carthy | M | 63 | 4 years | |
| Richard Paul Kivel | M | 57 | 3 years | |
| Harry Penner | M | 78 | 8 years | |
| Si Moon Hwang | M | 55 | 3 years | |
| Jordan P. Karp | M | 57 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 years |
| Mads Krogsgaard Thomsen | M | 63 | 30 years | |
| Donald W. Fallon | M | 69 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 years |
| Rakesh Soni | M | 68 | 7 years | |
| David Martin McIntosh | M | 65 | 11 years | |
| Carsten Hellmann | M | 60 | - | |
| Richard Rodgers | M | 57 | 6 years | |
| Michael E. Lewis | M | 72 | 9 years | |
| Joseph J. Krivulka | M | 73 | 9 years | |
| Hanne Damgaard Jensen | F | - | 4 years | |
| Ely Benaim | M | 63 | 4 years | |
| David Sack | M | - |
National Institute of Mental Health
| 4 years |
| Grethe Nørskov Rasmussen | M | 62 | 11 years | |
| Jette Traulsen | M | - | 5 years | |
| Søren Thuesen Pedersen | M | 59 | 24 years | |
| Stig Strøbæk | M | 60 | 30 years | |
| James D. Crapo | M | 81 | - | |
| Erik Michael Degn | M | - | 16 years | |
| Henrik Poulsen | M | 57 | 1 years | |
| Stephanie McSwain | F | - | - | |
| Lars Green | M | 57 | 27 years | |
| Peter Jens Lindholm Kurtzhals | M | - | 28 years | |
| Henrik Juuel | M | 59 | - | |
| Peder Holk Nielsen | M | 67 | 5 years | |
| René Djurup | M | - | 4 years | |
| Christopher Stanley | M | - | - | |
| Liselotte Hyveled | F | 58 | 26 years | |
| Zaiton binti Jamaluddin | F | 65 | 8 years | |
| Zhong Zhao | M | 57 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 6 years |
| Tae-Heum Jeong | M | - | 14 years | |
| Leif Kongerslev | M | 71 | - | |
| Jack Nielsen | M | 60 | 11 years | |
| Thomas Videbaek | M | 63 | - | |
| David P. Nowotnik | M | 75 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 4 years |
| Steven Paul | M | 73 |
National Institute of Mental Health
| 5 years |
| Carsten Boess | M | 57 | 13 years | |
| Shayne C. Gad | M | - | - | |
| Anker Gunvald Lundemose | M | 63 | 4 years | |
| Nicholas Landekic | M | 65 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 5 years |
| Valerie D. Riddle | M | 63 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | - |
| Joseph Klein | M | 62 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 7 years |
| Richard P. Burgoon | M | - | - | |
| Bruce Carter | M | 80 | 4 years | |
| Jan Öhrström | M | 67 | 9 years | |
| Lisa M. Nolan | M | 61 | 3 years | |
| David P. Wright | M | 75 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 years |
| Claus Tycho Bræstrup | M | 79 | 10 years | |
| Christian Hansen | M | 58 | 7 years | |
| Thomas Dyrberg | M | 69 | 10 years | |
| Jan Mikkelsen | M | 65 | 11 years | |
| Kirsten Drejer | M | 68 | 9 years | |
| Francesca M. Cook | F | 58 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 years |
| David Savello | M | 78 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 years |
| Jens Jesper Ovesen | M | 67 | 4 years | |
| Anders Hedegaard | M | 63 | 9 years | |
| Susanne Hayes | F | - | 10 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 47 | 56.63% |
| Denmark | 36 | 43.37% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Peter David Suzdak
- Personal Network
